全文获取类型
收费全文 | 6492篇 |
免费 | 461篇 |
国内免费 | 153篇 |
专业分类
耳鼻咽喉 | 92篇 |
儿科学 | 94篇 |
妇产科学 | 106篇 |
基础医学 | 336篇 |
口腔科学 | 66篇 |
临床医学 | 322篇 |
内科学 | 550篇 |
皮肤病学 | 61篇 |
神经病学 | 114篇 |
特种医学 | 493篇 |
外国民族医学 | 3篇 |
外科学 | 1267篇 |
综合类 | 453篇 |
预防医学 | 60篇 |
眼科学 | 35篇 |
药学 | 188篇 |
1篇 | |
中国医学 | 40篇 |
肿瘤学 | 2825篇 |
出版年
2024年 | 5篇 |
2023年 | 100篇 |
2022年 | 121篇 |
2021年 | 266篇 |
2020年 | 236篇 |
2019年 | 236篇 |
2018年 | 253篇 |
2017年 | 197篇 |
2016年 | 276篇 |
2015年 | 258篇 |
2014年 | 406篇 |
2013年 | 465篇 |
2012年 | 338篇 |
2011年 | 311篇 |
2010年 | 234篇 |
2009年 | 331篇 |
2008年 | 353篇 |
2007年 | 357篇 |
2006年 | 306篇 |
2005年 | 265篇 |
2004年 | 219篇 |
2003年 | 170篇 |
2002年 | 153篇 |
2001年 | 153篇 |
2000年 | 112篇 |
1999年 | 114篇 |
1998年 | 120篇 |
1997年 | 86篇 |
1996年 | 58篇 |
1995年 | 68篇 |
1994年 | 65篇 |
1993年 | 47篇 |
1992年 | 48篇 |
1991年 | 31篇 |
1990年 | 25篇 |
1989年 | 40篇 |
1988年 | 37篇 |
1987年 | 18篇 |
1986年 | 34篇 |
1985年 | 30篇 |
1984年 | 28篇 |
1983年 | 15篇 |
1982年 | 24篇 |
1981年 | 26篇 |
1980年 | 25篇 |
1979年 | 19篇 |
1978年 | 8篇 |
1977年 | 6篇 |
1976年 | 7篇 |
1972年 | 2篇 |
排序方式: 共有7106条查询结果,搜索用时 15 毫秒
1.
2.
Place et modalités de l’irradiation postopératoire dans la prise en charge des métastases cérébrales
《Cancer radiothérapie》2020,24(6-7):477-481
Metastases are the most common brain tumors. After surgery, stereotactic radiotherapy (SRT) of the resection cavity is the standard of care. Data from two randomized trials indicate that SRT to the surgical bed is an effective treatment in reducing local failure as compared with observation, while reducing the risk of cognitive deterioration and maintaining quality of life as compared with whole brain radiation therapy. Local control appears higher after hypofractionated SRT compared to single-fraction SRT. Several questions such as target volumes, the optimal regimen in particular for large tumor bed, strategies to reduce the risk of lepto-meningeal recurrence, and the treatment sequence still need to be answered. 相似文献
3.
4.
Breast carcinoma is a major cause of morbidity and mortality in women. The study of bone pathologies presents considerable potential in anthropology, paleopathology, forensic science and medicine. In this paper, we present and discuss metastatic lesions found in the skeletons of known individuals from the CAL Milano Cemetery Skeletal Collection, clinically diagnosed with breast cancer during life. Fourteen skeletons from a contemporary and identified collection were macroscopically studied and metastases were identified by comparison with clinical literature. As a result, bone metastases were observed in 43% of the study sample. They were located most commonly on the ribs (28.1%), pelvic girdle (19.8%), vertebrae (15.6%), skull (15.6%), scapulae (10.2%) as well as proximal segment of the femora (8.4%) and humeri (2.4%) respectively, favoring sites of high vascularization. The majority of the lesions were osteolytic, although osteoblastic and mixed metastases did occur. Osteolytic metastases appear as coalescent porosity or round to oval perforating lesions on bones with denticulated margins and pitted surrounding bone, whereas osteoblastic metastases thickened the existing trabecula (spongiosclerosis). Mixed metastases were perforating lytic lesions exposing the osteoblastic activity in the underlying trabecular bone. These results, consistent with the data from the literature, strengthen the diagnostic criteria for metastases and illustrate the aspect of bone metastases in breast carcinoma. 相似文献
5.
6.
《European journal of surgical oncology》2019,45(12):2353-2359
IntroductionMajor hepatectomy (MH) is often needed in the curative management of intrahepatic cholangiocarcinoma (IHCC) and colorectal liver metastases (CRLM). While similar outcomes could be expected after MH for IHCC and CRLM, outcomes seem worse after MH for IHCC. A better understanding of such differences might help improving perioperative outcomes but comprehensive analysis are lacking.MethodsAll patients undergoing curative intent MH for IHCC or CRLM from 2003 to 2009 were included from two dedicated multi-institutional datasets. Preoperative management and short-term outcomes after MH were first compared. Independent predictors of postoperative mortality and morbidity were identified.ResultsAmong 827 patients, 333 and 494 patients underwent MH for IHCC and CRLM, respectively. Preoperative portal vein embolization was more frequently performed in the CRLM group (p < 0.001). MH in the IHCC group required more extended resection (p < 0.001). Postoperative mortality and severe morbidity rates were significantly higher in the IHCC group (7.2% vs. 1.2% and 29.7% vs. 11.1%, p < 0.001, respectively). Main causes for mortality were postoperative liver failure and deep surgical site infection. MH for IHCC was an independent risk factor for mortality (p < 0.001) and severe morbidity (p < 0.001). After propensity score matching (212 patients in each group), the aforementioned differences regarding outcomes remained statistically significant.ConclusionThis study suggests that IHCC patients are inherently more at risk after MH as compared to CRLM patients. Considering that postoperative liver failure was the most frequent cause of death, preoperative planning might have been inadequate in the setting of IHCC while more complex/extended resections should be expected. 相似文献
7.
Apatinib, an oral small molecular receptor tyrosine kinase inhibitor (TKI) developed first in China, exerts antiangiogenic and antineoplastic function through selectively binding and inhibiting vascular endothelial growth
factor receptor 2 (VEGFR-2). In this study, we aimed to explore the efficacy and safety profile of apatinib
monotherapy, or combined with chemotherapy or endothelial growth factor receptor (EGFR)-TKI in heavily
pretreated non-small cell lung cancer (NSCLC) patients with brain metastases. We performed a retrospective
analysis for relapsed NSCLC patients with brain metastases from our institute, who received apatinib
(250 mg or 500 mg p.o. qd) monotherapy, or combination with EGFR-TKI or chemotherapy as second or
more line systemic therapy until disease progression or unacceptable toxicity occurred. The objective response
rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), median overall survival
(mOS), and safety were analyzed. A total of 26 eligible patients were included: 24 patients diagnosed with
adenocarcinoma, 2 with squamous carcinoma, and 14 patients harboring EGFR sensitizing mutations. The
mPFS and mOS were 4.93 (range, 0.27−32.91; 95% CI 3.64−6.22) and 14.70 (range, 0.27−32.91; 95% CI
0.27−43.60) months for the whole group. The ORR and DCR were 7.7% (2/26) and 69.2% (18/26) for the
entire lesions, and 7.7% (2/26) and 79.6% (20/26) for brain metastases, respectively. Compared with patients
who received apatinib monotherapy, patients who received apatinib combination treatment had more favorable
mPFS (11.77 vs. 2.27 months, p<0.05) and mOS (24.03 vs. 6.07 months, p<0.05). Treatment-related toxicities
were tolerable including grade 1/2 hypertension, hand-and-foot syndrome, fatigue, nausea, liver dysfunction,
myelosuppression, skin rash, and palpitation. In conclusion, apatinib exhibited high activity and good tolerance
for NSCLC patients with brain metastasis, and it might become a potential choice for metastatic brain tumors
in NSCLC patients. 相似文献
8.
目的 观察微波消融(microwave ablation,MWA)联合经皮穿刺椎体成形术(percutaneous vertebroplasty,PVP)治疗腰椎转移瘤的临床疗效。方法 回顾性分析2016年6月至2019年6月广西医科大学附属肿瘤医院收治的50例腰椎转移瘤患者的临床资料,其中行经皮椎体成形术26例(PVP 组),经皮微波消融联合经皮椎体成形术24例(PVP+MWA组)。观察两组患者疼痛、功能状态以及骨水泥外渗情况和术后肿瘤复发率。结果 随访6~36个月,PVP组VAS评分从术前的(7.58±1.06) 分降至术后1个月的(3.27±1.40) 分和术后6个月的(3.08±1.60) 分;PVP+MWA组从术前的(7.67±1.05) 分降至术后1个月的(3.04±1.20) 分和术后6个月的(2.96±1.46) 分,两组术后 1个月及6个月的VAS评分低于术前(均P<0.05),但重复测量方差显示,组间效应差异无统计学意义(F=0.223,P=0.801)。术后1个月,PVP组的KPS评分较术前提升(21.50±11.32) 分,PVP+MWA组较术前提升(19.92±13.19) 分,两者差异无统计学意义(t=0.457,P=0.650)。PVP+MWA 组的骨水泥外渗率(12.5% vs 38.5%,P=0.037)和肿瘤复发率(8.3% vs 30.8%,P=0.048)均低于PVP 组。结论 经皮穿刺椎体成形术单独或联合微波消融治疗腰椎转移瘤均可取得较好临床疗效,两者联合在减少骨水泥外渗及局部肿瘤控制中更有优势。 相似文献
9.
10.